REVIEW ARTICLE

Prognostic value of left atrial volume index in acute coronary syndrome: A systematic review and meta-analysis

Artan Ahmeti | Feriz S. Bytyçi | Agata Bielecka-Dabrowa | Ibadete Bytyçi | Michael Y. Henein

1Clinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo
2Medical Faculty, University of Prishtina, Prishtina, Kosovo
3Main Family Medical Center, Prishtina, Kosovo
4Department of Hypertension, Medical University of Lodz, Lodz, Poland
5Institute of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
6Molecular and Clinic Research Institute, St George University, London, UK
7Brunel University, London, UK

Correspondence
Ibadete Bytyçi, Clinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo
Email: i.bytyci@hotmail.com

Abstract
Background: In the absence of mitral valve disease, increased left atrial volume (LAV) is a marker of diastolic dysfunction and long-standing elevated left ventricle (LV) pressure. The aim of this study was to assess the role of increased baseline LAV in predicting clinical outcome of patients presenting with acute coronary syndrome (ACS).

Methods: We systematically searched all electronic databases up to September 2020 in order to select clinical trials and observational studies, which assessed the predictive role of LAV indexed (LAVI) on clinical outcome in patients with ACS. Primary clinical endpoints were as follows: major adverse cardiac events (MACE), all-cause mortality and hospitalization. Secondary endpoints were in-hospital complications.

Results: A total of 2,705 patients from 11 cohort studies with a mean follow-up of 18.7 ± 9.8 months were included in the metaanalysis. Patients with low LAVI had low risk for MACE (15.9% vs. 33.7%; p < .01), long-term all-cause mortality (9.14% vs. 18.1%; p < .01), short-term mortality (3.31% vs. 9.38%; p = .02) and lower hospitalization rate (11.6% vs. 25.5%; p < .01) compared to patients with increased LAVI. Atrial fibrillation and cardiogenic shock as in-hospital events were lower (p < .05 for all) in patients with low LAVI but ventricular fibrillation/tachycardia was not different between groups (p = .14).

Conclusion: Increased LAVI is an independent predictor of outcome in patients with ACS. Thus, assessment of LA index in these patients is important for better risk stratification and guidance towards optimum clinical management.

KEYWORDS
acute coronary syndrome, clinical outcome, left atrial volume
1 | INTRODUCTION

Increased left atrial (LA) size is associated with raised left ventricular filling (LV) pressure and poor clinical outcome, particularly in patients with heart failure (HF) due to diastolic dysfunction (Dokainish et al., 2005). LA volume has been proposed as the best measure of LA enlargement compared with the simple antero-posterior diameter, hence has become the recommended method for measuring LA size by echocardiography (Abhayaratna et al., 2006). LA volume indexed to body surface area (LAVI) has been suggested as a marker for severity and duration of diastolic dysfunction (DD) as well as a predictor of related clinical events such as atrial fibrillation, congestive heart failure, and embolic stroke (Tsang et al., 2002). Arterial hypertension, ventricular hypertrophy and other cardiovascular disorders (CV) are associated with left ventricular diastolic dysfunction (LVDD), raised filling pressures and atrial remodelling due to chronic pressure overload (Bytyçi & Bajraktari, 2016).

In patients with acute coronary syndrome (ACS), left ventricular ejection fraction (LVEF) (Moss, 1984), the ratio of peak early-to-late LV filling velocities (E/A), E-wave deceleration time (DcT; Nijland et al., 1997; Sestili et al., 2007) and the ratio of early diastolic LV filling velocity to that of mitral annular velocity (E/e’Alam et al., 2007; Hillis et al., 2004) have been shown to be good prognostic echocardiographic markers. LAVI at hospital admission has also been reported as an indicator of the prognosis, with values of 32 ml/m² or more associated with poor prognosis (Gunasekaran et al., 2012; Patel et al., 2011). The aim of this study was to meta-analyse the existing evidence about the prognostic value of LA volume in predicting clinical outcome in patients presenting with ACS.

2 | METHODS

We followed the 2009 guidelines preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement (Moher et al., 2009), amendment to the Quality of Reporting of Meta-analyses statement (Higgins & Green, 2009). Due to the study design (meta-analysis), neither Institutional Review Board approval nor patient informed consent was needed.

2.1 | Search strategy

We systematically searched PubMed, Medline, EMBASE, Scopus, Google Scholar and the Cochrane Central Registry; up to September 2020 in order to select clinical trials and observational studies, which assessed the predictive role of LAVI for clinical outcome in patients with ACS, using the following keywords: “Left atrial volume index” OR “LAVI” AND “Acute coronary syndrome” OR “ACS” OR “Acute myocardial infarction” OR “AMI” OR “ST elevation myocardial infarction” OR “Non ST elevation myocardial infarction” AND “Clinical outcomes”. Additional searches for potential trials included the references of review articles on that issue, and the abstracts from selected congresses: scientific sessions of the European Society of Cardiology (ESC), the American Heart Association (AHA), American College of Cardiology (ACC) and European Association of Cardiovascular Imaging (EACVI).

The wild-card term *** was used to increase the sensitivity of the search strategy. The literature search was limited to studies in humans which was written in English. Two reviewers (A.A. and F.S.B.) independently evaluated each article, and no filters were applied.

2.2 | Study selection

Inclusion criteria were as follows: (a) studies investigated ACS patients with measurements of LAVI, (b) reporting LAVI cut-off value of (32 or 34 ml/m²), (c) reporting short- and/or long-term outcome, (d) follow-up and (e) enrolled population of adults aged ≥ 18 years, and (f) only studies in English.

Exclusion criteria were as follows: (a) no report based on LAVI cut-off, (b) insufficient statistical data to compare two groups, (c) no follow-up, (d) studies not in humans and (e) studies not in English.

2.3 | Outcome variables

Primary clinical endpoints were as follows: major adverse cardiac events (MACE), long-term all-cause mortality (during follow-up), short-term all-cause mortality (within 30 days after hospital admission) and hospitalization. Secondary endpoints were in-hospital complications such as ventricular fibrillation (VF), ventricular tachycardia (VT), atrial fibrillation (AF) and cardiogenic shock, long-term (during follow-up) all-cause mortality and short-term (within 30 days of procedure) all-cause mortality.

2.4 | Data extraction

Eligible studies were reviewed, and the following data were abstracted: (a) first author’s name; (b) year of publication; (c) study design; (d) data on two arms: low and increased LAVI; (e) patients’ baseline characteristics; (f) mean follow-up period; and (g) age and gender of participants.

2.5 | Quality assessment

Assessment of risk of bias in cohort studies we used the Newcastle–Ottawa Scale (NOS). The risk of bias in each study was judged to be “good,” “fair” or “poor” (Zeng et al., 2015).

2.6 | Statistical analysis

The meta-analysis was conducted using statistical analysis, performed using the RevMan (Review Manager [RevMan] version 5.1,
### Table 1: Main characteristics of trials included in the study

<table>
<thead>
<tr>
<th>Study (trial) year</th>
<th>Study design</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Sample size (LAVI↓/LAVI↑)</th>
<th>Primary endpoints</th>
<th>Other endpoints</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Møller 2003</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>Patients with Prosthetic mitral valve and MS</td>
<td>314 (172/142)</td>
<td>All-cause mortality</td>
<td>Intrahospital complications</td>
<td>15 ± 9 months</td>
</tr>
<tr>
<td>Beinart 2004</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>NR</td>
<td>396 (332/63)</td>
<td>MACE</td>
<td>Intrahospital complications</td>
<td>36 months</td>
</tr>
<tr>
<td>Meris 2009</td>
<td>CT (VALANT) secondary analysis</td>
<td>AMI patients</td>
<td>Contraindications to ACE/ARB, valvular disease</td>
<td>502 (385/117)</td>
<td>All-cause mortality</td>
<td>CV death hospitalization</td>
<td>20.7 ± 1.8 months</td>
</tr>
<tr>
<td>Antoni 2011</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>AF patients</td>
<td>320 (270/50)</td>
<td>All-cause mortality</td>
<td>Hospitalization</td>
<td>27 ± 14 months</td>
</tr>
<tr>
<td>Sakaguchi 2011</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>AF patients Valvular disease</td>
<td>205 (143/62)</td>
<td>MACE</td>
<td>CV death hospitalization</td>
<td>27 ± 16 months</td>
</tr>
<tr>
<td>Cho 2012</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>Heart failure Atrial fibrillation</td>
<td>253 (115/138)</td>
<td>All-cause mortality</td>
<td>Hospitalization Heart failure</td>
<td>30.8 ± 7.5 months</td>
</tr>
<tr>
<td>Salehi 2013</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>Cardiac arrest Severe disease (valvular disease)</td>
<td>100 (78/22)</td>
<td>MACE death</td>
<td>Stroke, MI</td>
<td>12 months</td>
</tr>
<tr>
<td>Jose Alves Secundo Junior 2014</td>
<td>Prospective observational study</td>
<td>ACS patients</td>
<td>Patients with prosthetic mitral valve and MS</td>
<td>171 (93/78)</td>
<td>MACE, death</td>
<td>Intrahospital complications</td>
<td>12 months</td>
</tr>
<tr>
<td>Cordeiro 2018</td>
<td>Prospective observational</td>
<td>AMI patients</td>
<td>Patients with Prosthetic mitral valve and MS</td>
<td>200 (116/84)</td>
<td>MACE, death, revascularization MI</td>
<td>Intrahospital complications</td>
<td>28 months</td>
</tr>
<tr>
<td>Badiger 2019</td>
<td>Prospective observational</td>
<td>ACS patients</td>
<td>Valvular disease (MS, MR, CHD etc.)</td>
<td>84 (58/26)</td>
<td>Intrahospital complications</td>
<td>Intra- hospital days</td>
<td></td>
</tr>
<tr>
<td>Nagula 2020</td>
<td>Prospective observational</td>
<td>ACS patients</td>
<td>Valvular disease Chronic CAD CKD</td>
<td>160 (76/84)</td>
<td>All-cause mortality</td>
<td>Intrahospital complications</td>
<td>12 months</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; AMI, acute myocardial infarction; CAD, coronary artery disease; CKD, chronic kidney disease; MACE, major adverse cardiac events; MI, myocardial infarction; MR, mitral regurgitation; MS, mitral stenosis; NR, non-reported.
The Cochrane Collaboration, Copenhagen, Denmark), with two-tailed testingsignificant. Relative risk (RR) ratios with 95% confidence interval (CI) are presented as summary statistics, whereas for continuous variable weighted mean differences (WMD) and 95% CI were used. The baseline characteristics are reported in mean and standard deviation (SD) which were estimated using the method described by Hozo et al. (2005). Analysis is presented in forest plots, the standard way for illustrating the results of individual studies and meta-analysis. The meta-analyses were performed with the random-effects model. Heterogeneity between studies was evaluated using Cochrane Q test and I² index. As a guide, I² < 25% indicated low, 25%–50% moderate and >50% high heterogeneity (Morton et al., 2004). To assess the additive (between-study) component of variance, the reduced maximum likelihood method (τ²) incorporated the occurrence of residual heterogeneity into the analysis (Higgins et al., 2003). Publication bias was assessed using visual inspections of funnel plots and Egger’s test.

3 | RESULTS

3.1 | Search results and trial flow

Of 3,184 articles identified in the initial searches, 261 studies were considered as potentially relevant. After stringent selection process, 11 articles met the inclusion criteria (Antoni et al., 2011; Badiger, 2019; Beinart et al., 2004; Cho et al., 2012; Cordeiro et al., 2018; Meris et al., 2009; Moller et al., 2003; Nagula et al., 2020; Sakaguchi et al., 2011; Salehi et al., 2013; Secundo Junior et al., 2014); one was secondary analysis of CTs (Antoni et al., 2011), and remaining 10 papers were observational studies. (Figure S1).

3.2 | Characteristics of included studies

Eleven studies with a total of 2,705 patients (1,819 with low LAVI and 886 with high LAVI), with mean follow-up duration of 18.7 ± 9.8 months, were included (Table 1). The two groups of patients had similar age (62.3 ± 7.8 vs. 60.4 ± 6.9 years, p = .21) and female gender distribution (29.2% vs. 34.1% p = .13). No difference was found between the two groups with regard to cardiovascular risk factors including smoking (45.4% vs. 42.8% p = .27) and dyslipidaemia (39.7% vs. 42.5% p = .34) but patients with high LAVI had more prevalent hypertension (62.4% vs. 51.7% p = .01), diabetes (33.9% vs. 27.05% p = .02), previous MI (25.1% vs. 17.6% p = .02), previous PCI (26.3% vs. 13.7% p < .01) and CABG (4.1% vs. 2.5% p < .01) compared to those with low LAVI (Table S1).

3.3 | Baseline LV and LA structure and function in the two groups of patients

Patients with low LAVI had smaller LV dimensions: LV end-diastolic dimension (LVEDD) with WMD −2.25 (95% CI, −3.33 to −1.26, p < .001), LV end-systolic dimension (LVESD) WMD −6 cm (95% CI, −11 to −0.10, p = .04) and higher LV EF with WMD 5.02 (95% CI, 3.25–6.80, p < .001). In the same group of patients, LV diastolic function was less compromised having lower E/e’ ratio WMD −1.48 (95% CI, −2.21 to −0.75, p < .001) compared to patients with high LAVI (Figure S2). The same group of patients with low LAVI had less prevalent moderate to severe mitral regurgitation (6.4% vs. 27.1%; p < .001), less prevalent multivessel coronary disease (53.8% vs. 60.6%; p = .04), less prevalent concomitant atrial fibrillation (4.16% vs. 8.1%; p = .04) and less patients with Killip class ≥2 compared to those with high LAVI. Wall motion score index (WMS) was not different between the two groups of patients (p = .61, Figure S3).

3.4 | Clinical outcome in the two patient groups

Patients with low LAVI had lower risk for MACE (15.9% vs. 33.7%; RR = 0.36, 95% CI: 0.27 to 0.47, p < .01, I² = 46%), long-term all-cause mortality (9.14% vs. 18.1%; RR = 0.33, 95% CI: 0.23 to 0.47, p < .01, I² = 33%), short-term all-cause mortality (3.31% vs. 9.38%; RR = 0.30, 95% CI: 0.11 to 0.85, p = .02, I² = 22%) and lower hospitalization rate (11.6% vs. 25.5%; RR = 0.35, 95% CI: 0.19 to 0.64, p < .01, I² = 66%) compared to patients with high LAVI (Figure 1).

3.5 | In-hospital events in the two groups of patients

The occurrence of atrial fibrillation (4.16% vs. 8.17%, p = .04) and cardiogenic shock (2.86% vs. 11.5%, p < .01) was significantly less in patients with low LAVI compared to those with high LAVI, but there was no difference in the prevalence of ventricular fibrillation/tachycardia (11.8% vs. 10.9%, p = .14, Figure 2) between the two groups.

3.6 | Risk of bias assessment

Many of the observational studies have good quality; below 25% of them have fair quality (Table S2). Also, there was no evidence for publication bias as evaluated by the Egger’s test for our findings.

4 | DISCUSSION

4.1 | Findings

The results of meta-analysing the available evidence for the clinical significance of the LAVI in ACS patients may be summarized as follows: (a) patients with low LAVI had less prevalent moderate to severe mitral regurgitation, less Killip class ≥2, less multivessel disease and better LV systolic and diastolic function compared to those with high LAVI; (b) Patients with low LAVI had lower risk of MACE, long- and short-term all-cause mortality and lower hospitalization rate...
compared to those with high LAVI; and (c) Patients with high LAVI had worse prognosis regarding in-hospital clinical complications.

4.2 Data interpretation

In the absence of significant mitral valve disease, increased LAVI is usually a surrogate for elevated LV end-diastolic pressure (LVEDP), worsening of LV diastolic dysfunction and raised cavity stiffness (Basnight et al., 1991). During ventricular diastole, the LA is directly exposed to diastolic LV pressure through the open mitral valve; hence, raised diastolic pressures are propagated to the LA and raise its cavity pressure. In view of the significantly thinner wall of the left atrium compared to the left ventricle, the myocardium of the former stretches in response to the increased pressure and the cavity enlarges. Such changes impact LA cavity in its ability to accommodate...
perpetual increases in pressures in response to those of the left ventricle (Bytyçi et al., 2019). As a result, LA pressure gets transmitted to the pulmonary venous system and causes pulmonary venous hypertension and eventually pulmonary arterial hypertension (Tossavainen et al., 2016). These changes in LV-LA and pulmonary circulation pressures should explain the significant worse clinical outcome we reported in patients with high LAVI compared to those with low LAVI. They also highlight the maintained LA function reserve in patients with low LAVI. While these pathophysiological LV-LA disturbances occur in all forms of LV disease, they tend to be exaggerated in patients presenting with ACS, since the acute loss of, even part, myocardial function in ventricles with, even, subclinical dysfunction are bound to cause acute rise of diastolic pressures and LA pressures, which themselves are known to increase the risk of ventricular arrhythmias (Appleton et al., 1993; Bytyçi et al., 2020; Gunasekaran et al., 2012; Nagarajarao et al., 2008), irrespective of the severity of coronary disease. Our findings also support this concept having shown that patients with high LAVI are bound to have worse diastolic function, and more prevalent multivessel coronary disease with its impact on overall LV function.

Furthermore, our results demonstrate that LA enlargement was associated with comorbidities such as hypertension, diabetes and previous ACS, which are known factors that impair LV diastolic function and raise its filling pressures (Anavekar et al., 2004; Foley et al., 1998). This may explain the relationship of higher prevalence of Killip and significant mitral regurgitation rate with their known clinical effects in patients with higher LAVI compared to those with low LAVI.

4.3 | Limitations

This analysis is based on the published data since 2003 that used a LAVI cut-off value of 32 ml/m² and the recently published cut-off value of 34 ml/m² according to recent guidelines. We did not have any data on the impact of changes in LAVI with treatment on clinical outcome, which could have altered our conclusion. We believe that the published data, which we identified and analysed, are collected based on conventional guidelines and the investigators adhered to conventionally used protocols.
4.4 | Clinical implications

In patients presenting with ACS, baseline measurement of LAVI in addition to conventional echocardiographic measurements of left and right ventricles may help to stratify patients at higher risk for acute adverse events from those at low risk, during follow-up. Patients presenting with Doppler echocardiographic markers of raised LA pressure should receive optimum pressure off-loading therapy in order to maintain optimum myocardial protection and avoid related complications. Echocardiography is a unique bedside investigation for these patients and does not need any special preparation or patient transportation to a special imaging unit.

5 | CONCLUSIONS

Increased LAVI is an independent predictor of outcome in patients presenting with ACS. The assessment of LA volume index in these patients in daily practice is important for better risk stratification and guidance towards optimum clinical management.

5.1 | CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

5.2 | AUTHOR’S CONTRIBUTION

A.A., I.B. and M.Y.H. designed and drafted the article. A.A., F.S.B. and A.B.D collected and analysed the data. I.B. and M.Y.H. interpreted the data and critically revised the article.

ORCID

Ibidete Bytyçi https://orcid.org/0000-0002-8996-4257

REFERENCES


SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.